Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Rangers are undefeated at .500 to keep World Series champs from a losing record with Bochy
ARLINGTON, Texas (AP) — The reigning World Series champion Texas Rangers are undefeated this season2024-05-21Day 4 Roundup: China Continues Dominance with 23 Golds, Another Shooting World Record Shattered
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Nursing Home in E China's Hangzhou Recruits Young People to Accompany Elderly People
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-2170th Anniversary of Founding of Gannan Tibetan Autonomous Prefecture Celebrated in Gansu
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Bella Hadid goes braless in a thigh
She is one of America's most recognisable fashion models.And Bella Hadid continued to show why she i2024-05-21Exhibition Featuring Paintings by Children of Xinjiang Held in Beijing
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment